Celestial, Good questions, that everyone probably is asking themselves. BUT, I suspect that there is more to the story than we will ever hear. Not sure if the 'problem' was present at the same rate in Europe or not. I suspect (based on the low occurance and some other rumblings) that the problem has something to do with a design issue in combination with correct use by the doctor. Imagine the conundrum.....if you recall the product, you (BSC) take the brunt of the blame even though doctor practice may be part of the problem. If you don't recall, the doc's may take offense in that BSC would be saying that the product wasn't being used correctly. BSC will come back strong....Taxus has proven itself and saves lives. No denying the benefits to diabetics. I believe that BSC truly cares about the patients, the doctors, the hospitals, etc. The Core
One exception to your earlier message...that there is a clear difference in clinical data on diabetics. The only "data" I have seen is on about 36 patients of which about 18 got TAXUS vs. the control. Hardly the basis for a clear diffence pronouncement. A randomized head to head comparison is needed to make this wish a reality and that is coming soon with the REALITY trial.